ERBB2 and breast carcinoma: Although best characterized in a breast cancer setting, studies have also looked at HER2-low prevalence across other solid organ tumours, where it has been found to account for approximately 47% of breast cancers and at similar rates in gastric, salivary gland, lung, endometrial, and urothelial cancers [40].